Innovative therapeutics

RSS Feed

Investors

Press Releases

Email Alerts

Oct 7, 2020
BioMarin, Pioneer in Rare Disease Treatments for Phenylketonuria (PKU), Receives FDA Approval of Label Expansion to Allow Maximum Dose of 60 mg for Palynziq® (pegvaliase-pqpz) Injection for Treatment of Adults with PKU

New Safety and Efficacy Data Out to 3 Years for First and Only Enzyme Therapy to Treat PKU Demonstrate Phe Lowering and Support Well-Characterized Safety Profile

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) to increase the...
- Photos 2
Oct 5, 2020
Scientific Luminary and MacArthur Fellowship Winner, Kevin Eggan, Ph.D., Joins BioMarin as Head of Research and Early Development

From Dish to Bedside: Tenured Harvard Professor, Started Multiple Biotechs, to Grow Early Stage Pipeline

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Company hired scientific luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., as Group Vice President, Head of Research and...
- Photos 1
Oct 2, 2020

BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307

2nd Investigational Gene Therapy in Clinic, Potential 3rd Therapy in PKU Franchise, 15+ Year Commitment to PKU Community

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a pioneer in developing treatments for phenylketonuria (PKU) and gene therapies, announced today that the U.S. Food and Drug Administration (FDA) has...
Sep 29, 2020

BioMarin to Participate in Upcoming Virtual Investor Conference

- Morningstar's Management Behind the Moat Conference on September 30 at 1:00pm ET

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer, will participate in Morningstar's Management Behind the Moat...
Sep 24, 2020

BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Doses First Participant in Global PHEARLESS Phase 1/2 Study of BMN 307 Gene Therapy

BioMarin Builds Upon 15+ Year Commitment to PKU Community with Potential 3rd Therapy in PKU Franchise

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has dosed the first participant in the global PHEARLESS Phase 1/2 study with BMN 307, an investigational gene therapy for the...